A pilot study of pembrolizumab and exemestane/leuprolide in premenopausal hormone receptor positive/HER2 negative locally advanced or metastatic breast cancer (PEER).

被引：0
|
作者：
Chen, I-Chun [1 ]
Lin, Ching-Hung [1 ]
Chang, Dwan-Ying [2 ]
Chen, Tom Wei-Wu [2 ]
Wang, Ming-Yang [1 ]
Ma, Wei-Li [2 ]
Lin, Yi-Ting [2 ]
Huang, Shu-Min [2 ]
Lu, Yen-Shen [2 ]
机构：
[1] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[2] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：1
相关论文
共 50 条
  • [21] THERAPEUTIC AND ECONOMIC VALUE OF EVEROLIMUS PLUS EXEMESTANE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE, HER2/NEU NEGATIVE ADVANCED BREAST CANCER
    Felix, J.
    Almeida, J.
    Ferreira, D.
    Rabiais, S.
    Vandewalle, B.
    VALUE IN HEALTH, 2015, 18 (07) : A453 - A453
  • [22] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
    E. Ciruelos
    M. Vidal
    E. Martínez de Dueñas
    N. Martínez-Jáñez
    Y. Fernández
    J. A. García-Sáenz
    L. Murillo
    F. Carabantes
    A. Beliera
    R. Fonseca
    J. Gavilá
    Clinical and Translational Oncology, 2018, 20 : 753 - 760
  • [23] HDAC inhibitor Tucidinostat plus exemestane as neoadjuvant therapy in patients with hormone receptor positive, HER2 negative breast cancer.
    Wang, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
    Ciruelos, E.
    Vidal, M.
    Martinez de Duenas, E.
    Martinez-Janez, N.
    Fernandez, Y.
    Garcia-Saenz, J. A.
    Murillo, L.
    Carabantes, F.
    Beliera, A.
    Fonseca, R.
    Gavila, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 753 - 760
  • [25] Stromal Tumor-Infiltrating Lymphocytes in Hormone Receptor-Positive/HER2 Negative Metastatic Breast Cancer
    Pabba, Anirudh
    Zels, Gitte
    De Schepper, Maxim
    Geukens, Tatjana
    Van Baelen, Karen
    Maetens, Marion
    Leduc, Sophia
    Nguyen, Ha-Linh
    Mahdami, Amena
    Van Cauwenberge, Josephine
    Borremans, Kristien
    Izci, Hava
    Hatse, Sigrid
    Neven, Patrick
    Wildiers, Hans
    Biganzoli, Elia
    van den Bogaert, Wouter
    Richard, Francois
    Floris, Giuseppe
    Desmedt, Christine
    MODERN PATHOLOGY, 2025, 38 (02)
  • [26] Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015
    Vanacker, Helene
    Bally, Olivia
    Kassem, Loay
    Tredan, Olivier
    Heudel, Pierre
    Bachelot, Thomas
    BULLETIN DU CANCER, 2015, 102 (06) : S47 - S52
  • [27] Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation
    den Brok, Wendie-Lou D.
    Speers, Caroline
    Lovedeep, Gondara
    Baxter, Emily
    Tyldesley, Scott
    Caroline, Lohrisch
    CANCER RESEARCH, 2015, 75
  • [28] Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
    E. Ciruelos
    G. Jerusalem
    M. Martin
    V. C. G. Tjan-Heijnen
    P. Neven
    J. Gavila
    F. Montemurro
    D. Generali
    I. Lang
    M. J. Martínez-Serrano
    M. F. Perelló
    P. Conte
    Clinical and Translational Oncology, 2020, 22 : 1857 - 1866
  • [29] Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population
    Ciruelos, E.
    Jerusalem, G.
    Martin, M.
    Tjan-Heijnen, V. C. G.
    Neven, P.
    Gavila, J.
    Montemurro, F.
    Generali, D.
    Lang, I.
    Martinez-Serrano, M. J.
    Perello, M. F.
    Conte, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (10): : 1857 - 1866
  • [30] Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
    Moy, Beverly
    Neven, Patrick
    Lebrun, Fabienne
    Bellet, Meritxell
    Xu, Binghe
    Sarosiek, Tomasz
    Chow, Louis
    Goss, Paul
    Zacharchuk, Charles
    Leip, Eric
    Turnbull, Kathleen
    Bardy-Bouxin, Nathalie
    Duvillie, Ladan
    Lang, Istvan
    ONCOLOGIST, 2014, 19 (04): : 346 - 347
12345